预防自身免疫介导的先天性心脏传导阻滞的治疗选择:系统综述
该系统综述纳入20项研究(含13项回顾性研究),涉及2134名抗Ro/La抗体阳性孕妇和2915次妊娠,评估多种治疗预防先天性心脏传导阻滞(CHB)的效果。因异质性无法进行荟萃分析;羟氯喹(HCQ)在预防CHB方面证据最多,但纳入研究存在高偏倚风险和不精确性。
要点
- HCQ作为一级预防在5项研究中的4项显示对CHB发生率有保护作用。
- HCQ预防复发仅1项有对照的研究显示保护作用。
- 糖皮质激素作为一级预防在3项研究中的2项显示保护作用,复发预防仅1项显示保护。
核心结论
- 在抗Ro/La抗体阳性孕妇预防CHB的多种治疗选择中,HCQ显示的证据最多,但纳入研究存在高偏倚风险和不精确性。
研究设计与样本
- 系统综述纳入20项研究,其中13项为回顾性研究,涉及2134名孕妇和2915次妊娠。
- 纳入标准为抗Ro/La抗体阳性孕妇接受治疗以预防CHB的研究,排除仅治疗已发生或发展中的CHB的研究。
- 因研究间异质性,无法进行荟萃分析。
主要发现
- HCQ作为一级预防在5项研究中的4项显示对CHB发生率有保护作用,预防复发仅1项有对照的研究显示保护作用。
- 糖皮质激素作为一级预防在3项研究中的2项显示对CHB发生率有保护作用,预防复发仅1项研究显示保护作用。
- IVIG有对照的研究显示对CHB复发无保护作用。
- 两项研究(IVIG和血浆置换)无对照组。
- 治疗的长期毒性研究不足。
临床怎么用
- 对于抗Ro/La抗体阳性孕妇,HCQ在预防CHB方面证据最多,但需注意纳入研究的高偏倚风险和不精确性。
- 糖皮质激素和IVIG的预防证据有限,IVIG有对照研究显示对复发无保护作用。
- 治疗决策时应考虑长期毒性研究不足的局限性。
局限性
- 纳入研究存在高偏倚风险和不精确性。
- 因异质性无法进行荟萃分析。
- 治疗的长期毒性研究不足。
- 未来研究应为前瞻性、比较现有治疗并记录不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Complete congenital heart block (CHB) due to anti-Ro/La antibodies in pregnancy can lead to adverse fetal outcomes and neonatal death. National and international guidelines do not recommend specific treatment for women identified with anti-Ro antibodies while pregnant. DESIGN: Systematic review of studies of pregnant women with anti-Ro/La antibodies undertaking treatment(s) to prevent CHB. Studies solely focused on treating developing or established CHB were excluded. MAIN OUTCOME MEASURE: CHB incidence. RESULTS: Of 1049 articles, 20 studies were eligible, of which 13 were retrospective. Sixteen studies contained usable data comparing various treatments (seven hydroxychloroquine (HCQ), six corticosteroids, two intravenous immunoglobulin (IVIG) and one each on combined HCQ and corticosteroids and plasmapheresis), including 2134 women and 2915 pregnancies. Meta-analysis was not possible due to heterogeneity. HCQ as primary prophylaxis showed protective effect on CHB incidence in four of five studies, whereas for preventing recurrence, only one study had a comparator arm, which showed a protective effect. Corticosteroids showed protective effect on CHB incidence as primary prophylaxis in two of three studies, whereas in recurrence, only one study showed protective effect. The IVIG study with a comparator showed no protective effect on CHB recurrence. Two studies (IVIG and plasmapheresis) had no comparator. The long-term toxicity of treatments was poorly investigated. CONCLUSION: HCQ showed the most evidence among various treatment options to prevent CHB in babies of women with anti-Ro/La antibodies. However, included studies had high risk of bias and imprecision. Future studies should be prospective, compare existing treatments and capture adverse effects.PROSPERO registration number CRD42023492934.
引用
- Agarwal A, Skoutelis N, Zhou Y, et al. Treatment options for preventing autoimmune-mediated congenital heart block: a systematic review. Arch Dis Child. 2025. PMID: 39890428. doi:10.1136/archdischild-2024-327570
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。